Skip To Content

Study ID: Novo Nordisk NN1218-4101

Title:

Efficacy and Safety of Faster-ating Insulin Aspart comparted to NovoRapid both in Combination with Insulin Degludec in Children and Adolescents with type 1 diabetes

Location:
Fargo Region, Sioux Falls Region
Principal Investigator:
Kurt Griffin, MD, PhD,Luis Casas, MD
Disease:
Stage:
Phase III
Status:
Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.